TY - JOUR AU - Sharmah, Bhaben AU - Borthakur, Amarjit AU - Manna, Prasenjit TI - PLGA‐Based Drug Delivery Systems: A Promising Carrier for Antidiabetic Drug Delivery JF - ADVANCED THERAPEUTICS J2 - ADV THER PY - 2024 SN - 2366-3987 DO - 10.1002/adtp.202300424 UR - https://m2.mtmt.hu/api/publication/34763312 ID - 34763312 AB - Poly(lactic‐ co ‐glycolic acid) (PLGA) nanoparticles have emerged as a versatile platform for drug delivery due to their biodegradability, biocompatibility, and tunable release kinetics. One of the primary applications of PLGA nanoparticles in diabetes management is the encapsulation and controlled release of insulin, overcoming the limitations of frequent injections. Such systems provide sustained and stable glycemic control, reducing the risk of hypoglycemia. Different types of PLGAs and their derivatives are used for preparing varieties of micro/nanocarriers to deliver insulin as well as diverse antidiabetic molecules, including glucagon‐like peptide‐1 (GLP‐1) and its analog (exendin‐4), crocetin, metformin hydrochloride, gliclazide, ferulic acid (FA), etc., to reduce hyperglycemia. Here the current state of research and development in PLGA‐based drug delivery systems for diabetes management are summarized. Various strategies employed to enhance the targeting specificity of PLGA nanoparticles in diabetes therapy are explored. The outcome will provide an insight into the drug delivery potential and efficiency of PLGA in managing hyperglycemia and that will be useful in designing novel therapeutic to improve better control of diabetes mellitus. As research in this field continues to progress, PLGA‐based systems hold great potential for revolutionizing the treatment paradigm for diabetes mellitus. LA - English DB - MTMT ER - TY - JOUR AU - Behzadifar, Shakila AU - Barras, Alexandre AU - Plaisance, Valérie AU - Pawlowski, Valérie AU - Szunerits, Sabine AU - Abderrahmani, Amar AU - Boukherroub, Rabah TI - Polymer-Based Nanostructures for Pancreatic Beta-Cell Imaging and Non-Invasive Treatment of Diabetes JF - PHARMACEUTICS J2 - PHARMACEUTICS VL - 15 PY - 2023 IS - 4 SP - 1215 SN - 1999-4923 DO - 10.3390/pharmaceutics15041215 UR - https://m2.mtmt.hu/api/publication/33784975 ID - 33784975 AB - Diabetes poses major economic, social, and public health challenges in all countries worldwide. Besides cardiovascular disease and microangiopathy, diabetes is a leading cause of foot ulcers and lower limb amputations. With the continued rise of diabetes prevalence, it is expected that the future burden of diabetes complications, early mortality, and disabilities will increase. The diabetes epidemic is partly caused by the current lack of clinical imaging diagnostic tools, the timely monitoring of insulin secretion and insulin-expressing cell mass (beta (β)-cells), and the lack of patients’ adherence to treatment, because some drugs are not tolerated or invasively administrated. In addition to this, there is a lack of efficient topical treatment capable of stopping the progression of disabilities, in particular for treating foot ulcers. In this context, polymer-based nanostructures garnered significant interest due to their tunable physicochemical characteristics, rich diversity, and biocompatibility. This review article emphasizes the last advances and discusses the prospects in the use of polymeric materials as nanocarriers for β-cell imaging and non-invasive drug delivery of insulin and antidiabetic drugs in the management of blood glucose and foot ulcers. LA - English DB - MTMT ER - TY - JOUR AU - Gao, Zejing AU - Wei, Yi AU - Ma, Guanghui TI - A review of recent research and development on GLP-1 receptor agonists-sustained-release microspheres JF - JOURNAL OF MATERIALS CHEMISTRY B J2 - J MATER CHEM B PY - 2023 SN - 2050-750X DO - 10.1039/D3TB02207B UR - https://m2.mtmt.hu/api/publication/34387379 ID - 34387379 AB - This review provides key points in the development of glucagon-like peptide-1 receptor agonist-loaded microspheres from three aspects: preparation methods, strategies to maintain peptide bioactivity, and control the drug release from microspheres. LA - English DB - MTMT ER - TY - JOUR AU - Immanuel, Handika TI - Kajian Rute Alternatif Pemberian Liraglutide dalam Penanganan Diabetes dan Obesitas JF - Jurnal Ilmu Farmasi dan Farmasi Klinik J2 - Jurnal Ilmu Farmasi dan Farmasi Klinik VL - 20 PY - 2023 IS - 2 SP - 75 SN - 1693-7899 DO - 10.31942/jiffk.v20i2.9299 UR - https://m2.mtmt.hu/api/publication/34471844 ID - 34471844 AB - Liraglutide adalah sebuah obat peptida yang digunakan untuk menangani diabetes tipe 2 dan obesitas. Liraglutide diberikan secara injeksi subkutan setiap harinya. Rute injeksi subkutan dapat menyebabkan rasa sakit dan ketidaknyamanan bagi beberapa pasien. Oleh sebab itu, penting untuk meninjau keefektifan dan keamanan rute alternatif ini untuk memastikan bahwa pasien memiliki akses ke pilihan pengobatan yang paling tepat dan nyaman. Rute pemberian alternatif seperti oral dan subkutan yang diperlama pelepasan obatnya, serta topikal, mulai dikembangkan. Artikel review deskriptif ini dibuat dengan metode penelaahan pustaka menggunakan kriteria inklusi dan eksklusi. Beberapa penelitian telah dilakukan untuk mengevaluasi efikasi dan keamanan liraglutide yang diberikan melalui rute alternatif seperti oral dan topikal. Liraglutide yang diberikan melalui rute oral menggunakan teknologi enkapsulasi telah menunjukkan manfaat yang serupa dengan liraglutide yang diberikan melalui injeksi subkutan, ditandai dengan adanya penurunan kadar glukosa darah serta penurunan berat badan yang sebanding. Pemberian liraglutide yang telah dienkapsulasikan melalui injeksi subkutan juga telah diketahui dapat memberikan durasi efek farmakologis yang lebih panjang, sehingga meminimalkan frekuensi pemakaian liraglutide. LA - English DB - MTMT ER - TY - JOUR AU - Lenders, Vincent AU - Koutsoumpou, Xanthippi AU - Phan, Philana AU - Soenen, Stefaan J. AU - Allegaert, Karel AU - de Vleeschouwer, Steven AU - Toelen, Jaan AU - Zhao, Zongmin AU - Manshian, Bella B. TI - Modulation of engineered nanomaterial interactions with organ barriers for enhanced drug transport JF - CHEMICAL SOCIETY REVIEWS J2 - CHEM SOC REV VL - 52 PY - 2023 IS - 14 SP - 4672 EP - 4724 PG - 53 SN - 0306-0012 DO - 10.1039/D1CS00574J UR - https://m2.mtmt.hu/api/publication/34028665 ID - 34028665 AB - This review discusses the strengths and shortcomings of different strategies to facilitate NP transport across barriers of organs and highlights key findings that can stimulate further advances in this field. LA - English DB - MTMT ER - TY - JOUR AU - Sahandi, Zangabad P. AU - Abousalman, Rezvani Z. AU - Tong, Z. AU - Esser, L. AU - Vasani, R.B. AU - Voelcker, N.H. TI - Recent Advances in Formulations for Long-Acting Delivery of Therapeutic Peptides JF - ACS APPLIED BIO MATERIALS J2 - ACS APPL BIO MATER VL - 6 PY - 2023 IS - 9 SP - 3532 EP - 3554 PG - 23 SN - 2576-6422 DO - 10.1021/acsabm.3c00193 UR - https://m2.mtmt.hu/api/publication/34070225 ID - 34070225 N1 - Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutics Science, Monash University, Parkville Campus, Parkville, VIC 3052, Australia Melbourne Centre for Nanofabrication, Victorian Node of the Australian National Fabrication Facility, Clayton, VIC 3168, Australia Commonwealth Scientific and Industrial Research Organization (CSIRO), Clayton, VIC 3168, Australia Department of Materials Science and Engineering, Monash University, Clayton, VIC 3800, Australia Export Date: 5 October 2023 Correspondence Address: Voelcker, N.H.; Drug Delivery, Parkville Campus, Australia; email: nicolas.voelcker@monash.edu LA - English DB - MTMT ER - TY - JOUR AU - Srivastav, Anurag Kumar AU - Karpathak, Supriya AU - Rai, Mohit Kumar AU - Kumar, Dinesh AU - Misra, Durga Prasanna AU - Agarwal, Vikas TI - Lipid based drug delivery systems for oral, transdermal and parenteral delivery: Recent strategies for targeted delivery consistent with different clinical application JF - JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY J2 - J DRUG DELIV SCI TEC VL - 85 PY - 2023 PG - 22 SN - 1773-2247 DO - 10.1016/j.jddst.2023.104526 UR - https://m2.mtmt.hu/api/publication/34269393 ID - 34269393 N1 - Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, 226014, India Department of Respiratory Medicine, King George's Medical University, Lucknow, 226003, India Centre for Bio-Medical Research, UP, Lucknow, 226014, India Export Date: 25 March 2024; Cited By: 6; Correspondence Address: V. Agarwal; Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, UP, 226014, India; email: vikasagr@yahoo.com; CODEN: JDDSA AB - Lipid based drug delivery systems (LBDDS) are valuable and biocompatible nano-carriers for the vehiculation and potential delivery of various hydrophilic, hydrophobic, or amphiphilic compounds. LBDDS have the advantage of targeted drug delivery, as free drugs may have poor targeting, higher systemic toxicity, and pos-sibilities of drug resistance. There is various type of lipid carrier systems for drug delivery based on the properties of drugs and clinical applications; nanoemulsion, microemulsion, lipid vesicles, and lipid nanoparticles. The era of targeted drug delivery is advancing from the superficial convention vesicles to the second generation of LBDDS by modulating the surface chemistry through modifying/surface functionalizing the lipid layer composition. The surfaces of lipid vehicles have been modified with small molecules, antibodies, peptides, and enzymes for tar-geted drug delivery and reduced toxicity. In this regard, polyethylene glycosylation (PEGylation) on the lipid surface was the first novel approach that improves blood circulation time and curtails opsonin resistance and clearance. However, multi-drug and multi-receptor strategies in the targeted-liposomal approach may be an innovative pathway to overcoming drug resistance while treating certain tumors. Several second-generation conventional drug delivery systems among liposomal formulations are at various stages of clinical trials. This review recapitulates the types of lipid formulations, characterization, and their applications in clinical aspects. Additionally, discuss the strategies for enhancement of disease targeting by surface functionalization with various entities to improve the drug delivery system. LA - English DB - MTMT ER - TY - JOUR AU - Wang, Wenrui AU - Zhang, Chuan AU - Zhang, Haolong AU - Li, Luyao AU - Fan, Tingting AU - Jin, Zhenjing TI - The alleviating effect and mechanism of GLP-1 on ulcerative colitis JF - AGING-US J2 - AGING-US PY - 2023 SN - 1945-4589 DO - 10.18632/aging.204953 UR - https://m2.mtmt.hu/api/publication/34104264 ID - 34104264 LA - English DB - MTMT ER - TY - JOUR AU - You, Jeongyun AU - Juhng, Seorin AU - Song, Jieun AU - Park, Jihyun AU - Jang, Mingyu AU - Kang, Geonwoo AU - Yang, Huisuk AU - Min, Hye Su AU - Shin, Jiwoo AU - Lee, Seri AU - Ko, Hyuk Wan AU - Jung, Hyungil TI - Egg Microneedle for Transdermal Delivery of Active Liraglutide JF - ADVANCED HEALTHCARE MATERIALS J2 - ADV HEALTHC MATER PY - 2023 SP - 2202473 SN - 2192-2640 DO - 10.1002/adhm.202202473 UR - https://m2.mtmt.hu/api/publication/33585012 ID - 33585012 LA - English DB - MTMT ER - TY - JOUR AU - Zhang, Li AU - Yang, Changwei AU - Song, Yingxiang AU - Sheng, Tao AU - Li, Junyan AU - Yu, Jicheng AU - Wu, Xiaohong AU - Ye, Xiao TI - Advances of nanoparticles in transmucosal drug delivery JF - NANO RESEARCH J2 - NANO RES PY - 2023 SN - 1998-0124 DO - 10.1007/s12274-023-6188-7 UR - https://m2.mtmt.hu/api/publication/34399044 ID - 34399044 LA - English DB - MTMT ER - TY - JOUR AU - Ziebarth, Jeferson AU - Mainardes, Rubiana Mara TI - Preparation, characterization and in vitro evaluation of chitosan nanoparticles for the oral delivery of GLP-1 analog liraglutide JF - JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY J2 - J THERM ANAL CALORIM VL - 148 PY - 2023 IS - 6 SP - 2443 EP - 2455 PG - 13 SN - 1388-6150 DO - 10.1007/s10973-022-11909-0 UR - https://m2.mtmt.hu/api/publication/33547049 ID - 33547049 LA - English DB - MTMT ER - TY - CHAP AU - Abderrahmani, Amar AU - Szunerits, Sabine AU - Dalle, Stephane AU - Boukherroub, Rabah ED - El Ouaamari, Abdelfattah ED - Boukerroub, Rabah ED - Szunerits, Sabine ED - Abderrahmani, Amar TI - Chapter 3. Optimizing the Current Type 2 Diabetes Antidiabetics with Nanotechnologies: Where Do We Stand? T2 - Nanotechnology for Diabetes Management PB - Royal Society of Chemistry CY - Cambridge SN - 9781839164705 T3 - Nanoscience & Nanotechnology Series PY - 2022 SP - 92 EP - 112 PG - 21 DO - 10.1039/9781839165498-00092 UR - https://m2.mtmt.hu/api/publication/33584317 ID - 33584317 LA - English DB - MTMT ER - TY - THES AU - Brunner, J TI - Unravelling the modulation of tight junctions: Molecular mechanisms and permeation enhancement PY - 2022 SP - 152 DO - 10.13097/archive-ouverte/unige:161111 UR - https://m2.mtmt.hu/api/publication/33580448 ID - 33580448 LA - English DB - MTMT ER - TY - THES AU - Christina, Fey TI - Establishment of an intestinal tissue model for pre-clinical screenings PY - 2022 DO - 10.25972/OPUS-24410 UR - https://m2.mtmt.hu/api/publication/32797332 ID - 32797332 LA - English DB - MTMT ER - TY - JOUR AU - H. TEAIMA, MAHMOUD AU - I. GEBRIL, MOSTAFA AU - ALLAH, FATHY I. ABD AU - EL-NABARAWI, MOHAMED A. TI - NIOSOMES VERSUS PRONIOSOMES AS PROMISING DRUG DELIVERY SYSTEMS IN TREATMENT OF DIABETES MELLITUS JF - INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICS J2 - INT J APP PHARM VL - 14 PY - 2022 IS - 5 SP - 32 EP - 40 PG - 9 SN - 0975-7058 DO - 10.22159/ijap.2022v14i5.44039 UR - https://m2.mtmt.hu/api/publication/33091992 ID - 33091992 N1 - Export Date: 26 January 2023 AB - Diabetes Mellitus (DM) has emerged as an epidemic that has affected millions of people globally in the last few decades. Conventional antidiabetic dosage forms have a lot of problems that necessitate searching for novel drug delivery systems to overcome these drawbacks. Niosomes and proniosomes have been used to carry a wide variety of antidiabetic drugs achieving controlled and sustained release, which improves patient compliance. This review article describes the fundamental aspects of niosomes and proniosomes, including their structural components, methods of preparation, advantages and drawbacks, characterization, factors affecting niosomes formation along with their application in the treatment of diabetes. It also highlights the participation of other drug delivery systems in the treatment of diabetes done, mainly in the last decade. LA - English DB - MTMT ER - TY - JOUR AU - Kósa, Dóra AU - Pető, Ágota AU - Fenyvesi, Ferenc AU - Váradi, Judit AU - Vecsernyés, Miklós AU - Budai, István AU - Németh, József AU - Siposné Fehér, Pálma AU - Bácskay, Ildikó AU - Ujhelyi, Zoltán TI - Oral Bioavailability Enhancement of Melanin Concentrating Hormone, Development and In Vitro Pharmaceutical Assessment of Novel Delivery Systems JF - PHARMACEUTICS J2 - PHARMACEUTICS VL - 14 PY - 2022 IS - 1 SP - 1 EP - 15 PG - 15 SN - 1999-4923 DO - 10.3390/pharmaceutics14010009 UR - https://m2.mtmt.hu/api/publication/32548835 ID - 32548835 N1 - Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, Debrecen, 4032, Hungary Doctoral School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei Körút 98, Debrecen, 4032, Hungary Institute of Healthcare Industry, University of Debrecen, Nagyerdei Körút 98, Debrecen, 4032, Hungary Faculty of Engineering, University of Debrecen, Ótemető Utca 2-4, Debrecen, 4028, Hungary Department of Pharmacology and Pharmacotherapy, University of Debrecen, Nagyerdei Körút 98, Debrecen, 4032, Hungary Export Date: 17 January 2022 Correspondence Address: Ujhelyi, Z.; Department of Pharmaceutical Technology, Nagyerdei Körút 98, Hungary; email: ujhelyi.zoltan@pharm.unideb.hu AB - The rapid progress in biotechnology over the past few decades has accelerated the large-scale production of therapeutic peptides and proteins, making them available in medical practice. However, injections are the most common method of administration; these procedures might lead to inconvenience. Non-invasive medications, such as oral administration of bio-compounds, can reduce or eliminate pain and increase safety. The aim of this project was to develop and characterize novel melanin concentrating hormone (MCH) formulations for oral administration. As a drug delivery system, penetration enhancer combined alginate beads were formulated and characterized. The combination of alginate carriers with amphiphilic surfactants has not been described yet. Due to biosafety having high priority in the case of novel pharmaceutical formulations, the biocompatibility of selected auxiliary materials and their combinations was evaluated using different in vitro methods. Excipients were selected according to the performed toxicity measurements. Besides the cell viability tests, physical properties and complex bioavailability assessments were performed as well. Our results suggest that alginate beads are able to protect melanin concentrating hormones. It has been also demonstrated that penetration enhancer combined alginate beads might play a key role in bioavailability improvement. These formulations were found to be promising tools for oral peptide delivery. Applied excipients and the performed delivery systems are safe and highly tolerable; thus, they can improve patients’ experience and promote adherence. © 2021 by the authorsLicensee MDPI, Basel, Switzerland. LA - English DB - MTMT ER - TY - JOUR AU - Xu, Weizhi AU - Kumar, Vinod AU - Cui, Cedric S. AU - Li, Xaria X. AU - Whittaker, Andrew K. AU - Xu, Zhi Ping AU - Smith, Maree T. AU - Woodruff, Trent M. AU - Han, Felicity Y TI - Success in Navigating Hurdles to Oral Delivery of a Bioactive Peptide Complement Antagonist through Use of Nanoparticles to Increase Bioavailability and In Vivo Efficacy JF - ADVANCED THERAPEUTICS J2 - ADV THER PY - 2022 SP - 2200109 SN - 2366-3987 DO - 10.1002/adtp.202200109 UR - https://m2.mtmt.hu/api/publication/33077666 ID - 33077666 N1 - Export Date: 26 January 2023 LA - English DB - MTMT ER - TY - JOUR AU - Akel, Hussein AU - Ismail, Ruba AU - Katona, Gábor AU - Sabir, Fakhara AU - Ambrus, Rita AU - Pannonhalminé Csóka, Ildikó TI - A comparison study of Lipid and Polymeric Nanoparticles in the Nasal Delivery of Meloxicam: Formulation, Characterization, and In Vitro Evaluation JF - INTERNATIONAL JOURNAL OF PHARMACEUTICS J2 - INT J PHARM VL - 604 PY - 2021 PG - 13 SN - 0378-5173 DO - 10.1016/j.ijpharm.2021.120724 UR - https://m2.mtmt.hu/api/publication/32032508 ID - 32032508 LA - English DB - MTMT ER - TY - JOUR AU - Akel, Hussein AU - Pannonhalminé Csóka, Ildikó TI - Formulation and In Vitro Comparison Study between Lipid-Based and Polymeric-Based Nanoparticles for Nose-to-Brain Delivery of a Model Drug for Alzheimer’s Disease JF - PROCEEDINGS J2 - PROCEEDINGS VL - 78 PY - 2021 IS - 1 PG - 11 SN - 2504-3900 DO - 10.3390/IECP2020-08680 UR - https://m2.mtmt.hu/api/publication/32167160 ID - 32167160 LA - English DB - MTMT ER - TY - JOUR AU - Akel, Hussein AU - Pannonhalminé Csóka, Ildikó AU - Ambrus, Rita AU - Bocsik, Alexandra AU - Gróf, Ilona AU - Mészáros, Mária AU - Szecskó, Anikó AU - Kozma, Gábor AU - Veszelka, Szilvia AU - Deli, Mária Anna AU - Kónya, Zoltán AU - Katona, Gábor TI - In Vitro Comparative Study of Solid Lipid and PLGA Nanoparticles Designed to Facilitate Nose-to-Brain Delivery of Insulin JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 22 PY - 2021 IS - 24 PG - 22 SN - 1661-6596 DO - 10.3390/ijms222413258 UR - https://m2.mtmt.hu/api/publication/32531953 ID - 32531953 N1 - Funding Agency and Grant Number: Ministry of Human Capacities, Hungary [TKP-2020]; National Research, Development and Innovation Office, HungaryNational Research, Development & Innovation Office (NRDIO) - Hungary [GINOP2.3.2-15-2016-00060] Funding text: The publication was founded by the Ministry of Human Capacities, Hungary (Grant TKP-2020), and by the National Research, Development and Innovation Office, Hungary (GINOP2.3.2-15-2016-00060) projects. LA - English DB - MTMT ER - TY - JOUR AU - Brunner, J. AU - Ragupathy, S. AU - Borchard, G. TI - Target specific tight junction modulators JF - ADVANCED DRUG DELIVERY REVIEWS J2 - ADV DRUG DELIV REV VL - 171 PY - 2021 SP - 266 EP - 288 PG - 23 SN - 0169-409X DO - 10.1016/j.addr.2021.02.008 UR - https://m2.mtmt.hu/api/publication/31979449 ID - 31979449 AB - Intercellular tight junctions represent a formidable barrier against paracellular drug absorption at epithelia (e.g., nasal, intestinal) and the endothelium (e.g., blood–brain barrier). In order to enhance paracellular transport of drugs and increase their bioavailability and organ deposition, active excipients modulating tight junctions have been applied. First-generation of permeation enhancers (PEs) acted by unspecific interactions, while recently developed PEs address specific physiological mechanisms. Such target specific tight junction modulators (TJMs) have the advantage of a defined specific mechanism of action. To date, merely a few of these novel active excipients has entered into clinical trials, as their lack in safety and efficiency in vivo often impedes their commercialisation. A stronger focus on the development of such active excipients would result in an economic and therapeutic improvement of current and future drugs. © 2021 The Author(s) LA - English DB - MTMT ER - TY - JOUR AU - Eissa, N.G. AU - Elsabahy, M. AU - Allam, A. TI - Engineering of smart nanoconstructs for delivery of glucagon-like peptide-1 analogs JF - INTERNATIONAL JOURNAL OF PHARMACEUTICS J2 - INT J PHARM VL - 597 PY - 2021 SN - 0378-5173 DO - 10.1016/j.ijpharm.2021.120317 UR - https://m2.mtmt.hu/api/publication/32000113 ID - 32000113 AB - Glucagon-like peptide-1 (GLP-1) receptor agonists are being increasingly exploited in clinical practice for management of type 2 diabetes mellitus due to their ability to lower blood glucose levels and reduce off-target effects of current therapeutics. Nanomaterials had viewed myriad breakthroughs in protecting peptides against degradation and carrying therapeutics to targeted sites for maximizing their pharmacological activity and overcoming limitations associated with their application. This review highlights the latest advances in designing smart multifunctional nanoconstructs and engineering targeted and stimuli-responsive nanoassemblies for delivery of GLP-1 receptor agonists. Furthermore, advanced nanoconstructs of sophisticated supramolecular assembly yet efficient delivery of GLP-1/GLP-1 analogs, nanodevices that mediate intrinsic GLP-1 secretion per se, and nanomaterials with capabilities to load additional moieties for synergistic antidiabetic effects, are demonstrated. © 2021 Elsevier B.V. LA - English DB - MTMT ER - TY - JOUR AU - Kim, Hyosuk AU - Jang, Hochung AU - Cho, Haeun AU - Choi, Jiwon AU - Hwang, Kwang Yeon AU - Choi, Yeonho AU - Kim, Sun Hwa AU - Yang, Yoosoo TI - Recent Advances in Exosome-Based Drug Delivery for Cancer Therapy JF - CANCERS J2 - CANCERS VL - 13 PY - 2021 IS - 17 SN - 2072-6694 DO - 10.3390/cancers13174435 UR - https://m2.mtmt.hu/api/publication/32247293 ID - 32247293 N1 - Funding Agency and Grant Number: Mid-career Researcher Program of Korea Institute of Science and Technology (KIST) [NRF-2019R1A2C2010408]; Brain Pool Program of Korea Institute of Science and Technology (KIST) [NRF-2020H1D3A1A02081401]; Intramural Research Program of Korea Institute of Science and Technology (KIST) Funding text: This work was supported by the Mid-career Researcher Program (NRF-2019R1A2C2010408), Brain Pool Program (NRF-2020H1D3A1A02081401), and Intramural Research Program of Korea Institute of Science and Technology (KIST). LA - English DB - MTMT ER - TY - JOUR AU - Purohit, Deepika AU - Manchanda, Deeksha AU - Makhija, Manish AU - Rathi, Jyoti AU - Verma, Ravinder AU - Kaushik, Deepak AU - Pandey, Parijat TI - An Overview of the Recent Developments and Patents in the Field of Pharmaceutical Nanotechnology JF - RECENT PATENTS ON NANOTECHNOLOGY J2 - RECENT PAT NANOTECH VL - 15 PY - 2021 IS - 1 SP - 15 EP - 34 PG - 20 SN - 1872-2105 DO - 10.2174/1872210514666200909154409 UR - https://m2.mtmt.hu/api/publication/32167158 ID - 32167158 LA - English DB - MTMT ER - TY - CONF AU - Ismail, Ruba AU - Pannonhalminé Csóka, Ildikó ED - Bíró, Tivadar TI - Potential of polymeric and Lipid based nanocarriers for oral GLP-1 analogue delivery T2 - II. Symposium of Young Researchers on Pharmaceutical Technology, Biotechnology and Regulatory Science PB - University of Szeged C1 - Szeged PY - 2020 SP - 14 EP - 14 PG - 1 DO - 10.14232/syrptbrs.2020.op9 UR - https://m2.mtmt.hu/api/publication/33634513 ID - 33634513 LA - English DB - MTMT ER - TY - JOUR AU - Kaplan, Mikhail A. AU - Sergienko, Konstantin V AU - Kolmakova, Anastasia A. AU - Konushkin, Sergey V AU - Baikin, Alexander S. AU - Kolmakov, Alexey G. AU - Sevostyanov, Mikhail A. AU - Kulikov, Alexander V AU - Ivanov, Vladimir E. AU - Belosludtsev, Konstantin N. AU - Antipov, Sergey S. AU - Volkov, Mikhail Yu AU - Shusharina, Natalya N. AU - Karaduleva, Elena V AU - Kozlov, Valery A. AU - Simakin, Alexander V AU - Gudkov, Sergey V TI - Development of a Biocompatible PLGA Polymers Capable to Release Thrombolytic Enzyme Prourokinase JF - JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION J2 - J BIOMAT SCI-POLYM E VL - 31 PY - 2020 IS - 11 SP - 1405 EP - 1420 PG - 16 SN - 0920-5063 DO - 10.1080/09205063.2020.1760699 UR - https://m2.mtmt.hu/api/publication/31501141 ID - 31501141 AB - The novelty of the work lies in the creation and study of the physical and biological properties of biodegradable polymer coatings for stents based on poly(lactic-co-glycolic acid) (PLGA). Polymer coatings are capable of prolonged and directed release of molecules with a high molecular weight, in particular, protein molecules of prourokinase (m.w. 54 kDa). A technology has been developed to create coatings having a relative elongation of 40% to 165% and a tensile strength of 25-65 MPa. Coatings are biodegradable; the rate of degradation of the polymer in an isotonic solution varies in the range of 0.05%-1.0% per day. The created coatings are capable of controlled release of the protein of prourokinase, while about 90% of the molecules of prourokinase retain their enzymatic activity. The rate of release of prourokinase can vary from 0.01 to 0.08 mg/day/cm(2). Coatings do not have a short-term toxic effect on mammalian cells. The mitotic index of cells growing on coatings is approximately 1.5%. When implanting the developed polymers in animals in the postoperative period, there are no complications. Histological examination did not reveal pathological processes. When implanting individual polymers 60 days after surgery, only traces of PLGA are detected. Thus, a biodegradable composite mechanically resistant polymer capable of prolonged release of the high molecular weight prourokinase enzyme has been developed. LA - English DB - MTMT ER - TY - JOUR AU - Nie, Xin AU - Chen, Zhejie AU - Pang, Lan AU - Wang, Lin AU - Jiang, Huajuan AU - Chen, Yi AU - Zhang, Zhen AU - Fu, Chaomei AU - Ren, Bo AU - Zhang, Jinming TI - Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds JF - INTERNATIONAL JOURNAL OF NANOMEDICINE J2 - INT J NANOMED VL - 15 PY - 2020 SP - 10215 EP - 10240 PG - 26 SN - 1176-9114 DO - 10.2147/IJN.S285134 UR - https://m2.mtmt.hu/api/publication/32005188 ID - 32005188 N1 - College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau999087, China Cited By :9 Export Date: 21 June 2022 Correspondence Address: Ren, B.; College of Pharmacy, China; email: renbo@cdutcm.edu.cn Correspondence Address: Zhang, J.; College of Pharmacy, China; email: cdutcmzjm@126.com LA - English DB - MTMT ER - TY - JOUR AU - Padhi, Santwana AU - Nayak, Amit Kumar AU - Behera, Anindita TI - Type II diabetes mellitus: a review on recent drug based therapeutics JF - BIOMEDICINE & PHARMACOTHERAPY J2 - BIOMED PHARMACOTHER VL - 131 PY - 2020 SN - 0753-3322 DO - 10.1016/j.biopha.2020.110708 UR - https://m2.mtmt.hu/api/publication/32005186 ID - 32005186 N1 - Cited By :157 Export Date: 30 September 2023 CODEN: BIPHE LA - English DB - MTMT ER - TY - JOUR AU - Ismail, Ruba AU - Thi, Nhu Quynh Phan AU - Flavia, Laffleur AU - Pannonhalminé Csóka, Ildikó AU - Andreas, Bernkop Schnurch TI - Hydrophobic ion pairing of a GLP-1 analogue for incorporating into lipid nanocarriers designed for oral delivery JF - EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS J2 - EUR J PHARM BIOPHARM VL - 152 PY - 2020 SP - 10 EP - 17 PG - 8 SN - 0939-6411 DO - 10.1016/j.ejpb.2020.04.025 UR - https://m2.mtmt.hu/api/publication/31320069 ID - 31320069 LA - English DB - MTMT ER -